-
Mashup Score: 0Fallacies of Using the Win Ratio in Cardiovascular Trials: Challenges and Solutions - 13 hour(s) ago
SummaryThe win ratio was introduced into cardiovascular trials as a potentially better way of analyzing composite endpoints to account for the hierarchy of clinical significance of their components…
Source: www.jacc.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 0
Context The direct thrombin inhibitor bivalirudin has been associated with better efficacy and less bleeding than heparin during coronary balloon angioplasty but has not been widely tested during contemporary percutaneous coronary intervention (PCI).Objective To determine the efficacy of…
Source: jamanetwork.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 11Transcatheter Aortic Valve Implantation in Low-Risk Tricuspid or Bicuspid Aortic Stenosis: The NOTION-2 Trial - 2 day(s) ago
AbstractBackground and Aims. Transcatheter aortic valve implantation (TAVI) has become the first choice to treat older patients with severe symptomatic aor
Source: academic.oup.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 34Win Ratio: A Seductive But Potentially Misleading Method for Evaluating Evidence from Clinical Trials - 2 day(s) ago
Correspondence to: Javed Butler, MD, MPH, MBA, Baylor Scott and White Research Institute, 3434 Oak St, Dallas, TX 75204, Email Baylor Scott and White Research Institute (J.B.), Dallas, TX. Food and Drug Administration, Silver Spring, MD (N.S.). Milton Packer, MD, Baylor Heart and Vascular Institute, 621 N Hall St, Dallas, TX 75226, Email Baylor University Medical Center (M.P.), Dallas, TX. The opinions expressed in this article are not necessarily those of the editors or of the American Heart Association.
Source: www.ahajournals.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 18Self-Expanding or Balloon-Expandable TAVR in Patients with a Small Aortic Annulus | NEJM - 1 month(s) ago
Patients with severe aortic stenosis and a small aortic annulus are at risk for impaired valvular hemodynamic performance and associated adverse cardiovascular clinical outcomes after transcatheter…
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 15
– New Labels Expand Treatable Population to ~70 Million Patients in U.S. – – First LDL-C Lowering Non-Statin Indicated for Primary Prevention Patients – …
Source: www.globenewswire.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 41A Placebo-Controlled Trial of PCI for Stable Angina | NEJM - 2 month(s) ago
Correspondence from The New England Journal of Medicine — A Placebo-Controlled Trial of PCI for Stable Angina
Source: www.nejm.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 2Amylyx's ALS treatment Relyvrio fails PhIII study, biotech to consider withdrawing drug - 2 month(s) ago
Relyvrio, Amylyx’s FDA-approved ALS drug, has failed a crucial Phase III trial, the company said on Friday, a major blow to what had been considered one of the few significant options available for the treatment of the deadly neurodegenerative disease. The failure is almost certain to put access to the
Source: endpts.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5Remembering Dr. Merrill Benson - Amyloidosis Research Consortium - 3 month(s) ago
The Amyloidosis Research Consortium extends our deepest, heartfelt condolences to the family and friends of Dr. Merrill Benson, world renowned amyloidosis expert, who passed away on September 11, 2021.
Source: arci.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 6
Don’t miss what’s happeningPeople on X are the first to know.Log inSign upSettingsPostPinak Shah, MD@PinakShahMDwhy I would not want another trial. Yes, could have done better (sham control). But we now have a therapy for a difficult problem that makes people feel better and is incredibly safe. Appropriate pt selection key and we have to beware of indication creep.11:45 AM · Feb 20, 2024665…
Source: x.comCategories: General Medicine News, CardiologistsTweet
@ADAlthousePhD @BartoszHudzik @DFCapodanno @Drroxmehran @drjohnm @FeliceGragnano @CaoDavide @DocSavageTJU @fischman_david @DrMarthaGulati @ErinMichos @KardiologieHH @EmanueleBarba13 @alaide_chief @HawranekMichal @Marta33717088 @PCRonline 3/ As @djc795 said, each approach has its pros & cons. You are clearly enthusiastic about WR. Here are some of recent publications that highlight pros & cons of WR (which I am sure you are familiar with). https://t.co/wEHxLFij2O https://t.co/XB346AYggW https://t.co/U7oUdXQGRl